CTLA4 and colorectal carcinoma: By using MSI CRC patient-derived organoids orthotopically injected into NSG humanized mice, Kücükköse et al. showed that anti-PD-1 or anti-CTLA-4 therapy reduced primary CRC size and eradicated liver metastases but had no effect on peritoneal metastases [212].